Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer

Journal of Urology

Volumn 185, Issue 3, 2011, Pages 841-847

  Reed, Shelby D ^a,b   Scales Jr , Charles D ^a,b   Stewart, Suzanne B ^b   Sun, Jielin ^c   Moul, Judd W ^b   Schulman, Kevin A ^a,b   Xu, Jianfeng ^c  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

chemoprevention; cost benefit analysis; finasteride; genetic; polymorphism; risk factors

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIANDROGEN; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGED; ANDROGEN THERAPY; ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; FAMILY HISTORY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SCREENING; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME;

5-ALPHA REDUCTASE INHIBITORS; AGED; COST-BENEFIT ANALYSIS; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS;

EID: 79851508702     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.10.078     Document Type: Article

References (30)

1. R.S. Svatek, J.J. Lee, and C.G. Roehrborn The cost of prostate cancer chemoprevention: a decision analysis model Cancer Epidemiol Biomarkers Prev 15 2006 1485
2. S.B. Zeliadt, R.D. Etzioni, and D.F. Penson Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer Am J Med 118 2005 850
3. R.S. Svatek, J.J. Lee, and C.G. Roehrborn Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis Cancer 112 2008 1058
4. G. Thomas, K.B. Jacobs, and M. Yeager Multiple loci identified in a genome-wide association study of prostate cancer Nat Genet 40 2008 310
5. J. Gudmundsson, P. Sulem, and T. Rafnar Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer Nat Genet 40 2008 281
6. S.L. Zheng, J. Sun, and F. Wiklund Cumulative association of five genetic variants with prostate cancer N Engl J Med 358 2008 910
7. J. Sun, B.L. Chang, and S.D. Isaacs Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations Prostate 68 2008 1257
8. Z. Kote-Jarai, D.F. Easton, and J.L. Stanford Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium Cancer Epidemiol Biomarkers Prev 17 2008 2052
9. R.A. Eeles, Z. Kote-Jarai, and G.G. Giles Multiple newly identified loci associated with prostate cancer susceptibility Nat Genet 40 2008 316
10. J. Xu, J. Sun, and A.K. Kader Estimation of absolute risk for prostate cancer using genetic markers and family history Prostate 69 2009 1565
11. National Cancer Institute DevCan - Probability of Developing or Dying of Cancer http://srab.cancer.gov/devcan/ Accessed August 19, 2009
12. I.M. Thompson, P.J. Goodman, and C.M. Tangen The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215
13. E. Arias United States life tables, 2001 National Vital Statistics Reports vol. 52, no. 14 2004 National Center for Health Statistics Hyattsville, Maryland http://www.cdc.gov/nchs/data/nvsr/nvsr52/nvsr52-14.pdf Accessed August 19, 2009
14. M.W. Kattan, J.A. Eastham, and A.M. Stapleton A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer J Natl Cancer Inst 90 1998 766
15. C.R. Pound, A.W. Partin, and M.A. Eisenberger Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591
16. J.L. Bosch, W.C. Hop, and W.J. Kirkels Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community Urology 46 1995 34
17. K.R. Yabroff, E.B. Lamont, and A. Mariotto Cost of care for elderly cancer patients in the United States J Natl Cancer Inst 100 2008 630
18. Bureau of Labor Statistics Consumer Price Index-All Urban Consumers http://data.bls.gov/cgi-bin/surveymost?cu Accessed August 19, 2009
19. W.S. Rubinstein, H. Jiang, and L. Dellefave Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for dialogue Genet Med 11 2009 629
20. C. Taneja, J. Edelsberg, and D. Weycker Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women J Am Coll Radiol 6 2009 171
21. N. Thiry, C. De Laet, and F. Hulstaert Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening Int J Technol Assess Health Care 25 2009 161
22. I.M. Thompson, C.M. Tangen, and H.L. Parnes Does the level of prostate cancer risk affect cancer prevention with finasteride? Urology 71 2008 854
23. J. Hornberger, M. Holodniy, and K. Robertus A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy Med Decis Making 27 2007 789
24. P.A. Ubel, R.A. Hirth, and M.E. Chernew What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 163 2003 1637
25. R.A. Hirth, M.E. Chernew, and E. Miller Willingness to pay for a quality adjusted life year: in search of a standard Med Decis Making 20 2000 332
26. A.M. Garber, and C.E. Phelps Economic foundations of cost-effectiveness analysis J Health Econ 16 1997 1
27. C. McCabe, K. Claxton, and A.J. Culyer The NICE cost-effectiveness threshold: what it is and what that means Pharmacoeconomics 26 2008 733
28. US Census Bureau Table 1: Annual Estimates of the Resident Population by Sex and Five-Year Age Groups for the United States: April 1, 2000 to July 1, 2008 (NC-EST2008-01) http://www.census.gov/popest/national/asrh/NC-EST2008/NC- EST2008-01.xls Accessed September 10, 2009
29. S.T. Stewart, L. Lenert, and V. Bhatnagar Utilities for prostate cancer health states in men aged 60 and older Med Care 43 2005 347
30. A.J. Stephenson, P.T. Scardino, and J.A. Eastham Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy J Natl Cancer Inst 98 2006 715